Here is some news about Plus Therapeutics (PSTV):
- Consensus Rating and Short Interest Ratio: Plus Therapeutics has a "Strong Buy" consensus rating, indicating positive sentiment among analysts1. The short interest ratio for PSTV is over 15, suggesting that there is potential for a short squeeze, as high short interest can lead to a rapid increase in the stock price if significant numbers of shorted shares are covered1.
consensus rating is strong buy; short interest ratio > 15(1)
| | | Interest Expenses (MRQ)($) | | | | Interest Expenses (MRQ) / Total Assets (MRQ) |
---|
0.32 | -9.55% | Strong Buy | 3.76M | 2025Q1 | 20250331 | 12.06M | 0.31 |
View 1 result

In conclusion, Plus Therapeutics (PSTV) is a stock with strong buy consensus and high short interest ratio, which could indicate potential for a short squeeze.